GenScript Gets EUA for COVID-19 Neutralizing Antibody Test Kit

The FDA has granted Piscataway, N.J.-based GenScript an Emergency Use Authorization for its cPass SARS-CoV-2 neutralizing antibody detection test.

It is the first commercially available test to specifically detect neutralizing antibodies for the coronavirus without the use of live virus, GenScript said.

The test measures the presence of antibodies in patients recovering from COVID-19 or who have received a vaccine, making it “a valuable tool for assessing vaccine performance,” the company said.